# Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

> **NCT00248430** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** melphalan
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00248430
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248430, "Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00248430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*